Our team: David Robinson
Fladgate LLP has advised Bluewater Bio, the provider of innovative wastewater treatment technologies, on a US$8m investment by private equity firm Liberation Capital.
The investment is being made through a revolving convertible debt facility with project co-investment rights. The investment proceeds will be used both for Bluewater Bio’s current and forecast working capital needs and include an exclusive right for Liberation Capital to invest in future water-related infrastructure projects brought by Bluewater Bio.
Liberation Capital is a global private equity fund specialising in project finance for renewable energy and water/wastewater solutions. It focuses on small infrastructure projects with a preference for technologies and solutions that turn waste products into constituents of value.
Bluewater Bio is a global specialist in the treatment of wastewater. Its flagship technology, HYBACS, is a high-performance cost-effective nutrient removal solution for municipal and industrial wastewater treatment, and in recent months Bluewater Bio has added to its technology portfolio through the acquisition of FilterClear filters, a range of high-performance multimedia filters, and Water Innovate, the Cranfield University spin-out.
Daniel Ishag, CEO Bluewater Bio, commented: “Bluewater Bio is delighted to be concluding this transaction with Liberation Capital. This represents the culmination of a process lasting several months in which we have worked closely with them to bring this to fruition. This transaction further validates Bluewater Bio’s achievements to date and Liberation Capital and its team is an ideal project financing platform partner for us going forward, enabling us to scale our business globally”.
Corporate partner David Robinson led the Fladgate team advising Bluewater Bio.